Press "Enter" to skip to content

Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research on the FDA’s ongoing investigation into valsartan and ARB class impurities and the agency’s steps to address the root causes of the safety issues

FDA describes the ongoing investigation into the ARB class impurities and agency’s steps to address the root causes of the safety issues

Also Read:   FDA allows marketing of new device to help treat carbon monoxide poisoning